# A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Source: https://onco.cc/trials/nct06682793/  
OnCo record `nct06682793` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of A2B395 in colorectal cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma and triple-negative breast cancer, run by A2 Biotherapeutics Inc., now recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression is a phase 1/2 interventional study registered as NCT06682793 by A2 Biotherapeutics Inc., with 240 participants planned, started 2025-05-22 and due to reach its primary completion in 2029-03-31. Interventions recorded: A2B395.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06682793
- Phase: 1/2
- Setting: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Sponsor: A2 Biotherapeutics Inc.
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT06682793: https://clinicaltrials.gov/study/NCT06682793

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)

---
JSON: https://onco.cc/api/v1/entities/nct06682793.json